Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 20,400 shares of the company’s stock in a transaction dated Thursday, April 10th. The shares were purchased at an average cost of $9.28 per share, with a total value of $189,312.00. Following the completion of the transaction, the chief executive officer now directly owns 1,987,500 shares in the company, valued at approximately $18,444,000. Opko Health Inc. (NYSE:OPK) shares after opening at $9.10 moved to $9.20 on last trade day and at the end of the day closed at $8.87. Company price to sales ratio in past twelve months was calculated as 37.95 and price to cash ratio as 19.71. Opko Health Inc. (NYSE:OPK) showed a negative weekly performance of -3.48%.
GlaxoSmithKline plc (NYSE:GSK)‘s stock had its “neutral” rating reiterated by equities research analysts at Bryan Garnier & Cie in a research note issued to investors on Thursday, AR Network reports. They currently have a GBX 1,755 ($29.36) target price on the stock. Bryan Garnier & Cie’s price target would suggest a potential upside of 13.08% from the stock’s previous close. GlaxoSmithKline plc (ADR) (NYSE:GSK) shares fell -1.50% in last trading session and ended the day on $51.76. GSK return on equity ratio is recorded as 114.20% and its return on assets is 17.70%. GlaxoSmithKline plc (ADR) (NYSE:GSK) yearly performance is 11.89%.
Spherix Inc. (NASDAQ:SPEX) CEO Anthony Hayes buy 4000 shares of SPEX in a transaction dated on April 11, 2014. Spherix Inc. (NASDAQ:SPEX) shares were bought at an average price of $2.35 for total worth of $9,400.00. Spherix Inc. (NASDAQ:SPEX) shares moved down -10.29% in last trading session and was closed at $2.18, while trading in range of $2.10 – $2.42. Spherix Inc. (NASDAQ:SPEX) year to date (YTD) performance is -72.95%.
Agios Pharmaceuticals (NASDAQ:AGIO) SVP Glenn Goddard sold 2,000 shares of Agios Pharmaceuticals stock on the open market in a transaction dated Monday, April 7th. The stock was sold at an average price of $45.17, for a total transaction of $90,340.00. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) weekly performance is 22.10%. On last trading day company shares ended up $43.32. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) distance from 50-day simple moving average (SMA50) is 19.61%. Analysts mean target price for the company is $58.67.
Leave a Reply